NASDAQ:ANIX - Nasdaq - US03528H1095 - Common Stock - Currency: USD
2.84
-0.08 (-2.74%)
The current stock price of ANIX is 2.84 USD. In the past month the price decreased by -10.97%. In the past year, price decreased by -12.62%.
Symbol | Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
ABBV | ABBVIE INC | 21.17 | 378.30B | ||
AMGN | AMGEN INC | 16.39 | 174.51B | ||
GILD | GILEAD SCIENCES INC | 25.47 | 146.22B | ||
VRTX | VERTEX PHARMACEUTICALS INC | 1683.76 | 125.39B | ||
REGN | REGENERON PHARMACEUTICALS | 15.5 | 77.34B | ||
ARGX | ARGENX SE - ADR | 231.21 | 36.10B | ||
ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 31.66B | ||
ONC | BEIGENE LTD-ADR | N/A | 26.47B | ||
BNTX | BIONTECH SE-ADR | N/A | 26.08B | ||
BIIB | BIOGEN INC | 9.13 | 22.01B | ||
NTRA | NATERA INC | N/A | 19.02B | ||
GMAB | GENMAB A/S -SP ADR | 24.89 | 15.34B |
Anixa Biosciences, Inc. is a biotechnology company, which engages in the development of therapies and vaccines focused on oncology and infectious disease. The company is headquartered in San Jose, California and currently employs 4 full-time employees. Its segments include CAR-T Therapeutics, Cancer Vaccines, Anti-Viral Therapeutics and Other. Its vaccine programs include the development of a preventative vaccine against triple negative breast cancer (TNBC), the most lethal form of breast cancer, as well as other forms of breast cancer and the development of a preventative vaccine against ovarian cancer. Its therapeutics programs include the development of a chimeric endocrine receptor T cell therapy, a novel form of chimeric antigen receptor T cell (CAR-T) technology, initially focused on treating ovarian cancer, which is being developed by its subsidiary, Certainty Therapeutics, Inc. (Certainty). Certainty is developing immuno-therapy drugs against cancer. The Company’s vaccine portfolio consists of technology focused on the immunization against specific retired proteins.
ANIXA BIOSCIENCES INC
3150 Almaden Expy Ste 250
San Jose CALIFORNIA 95118 US
CEO: Amit Kumar
Employees: 5
Company Website: https://www.anixa.com/
Investor Relations: http://www.ir.anixa.com
Phone: 14087089808
The current stock price of ANIX is 2.84 USD. The price decreased by -2.74% in the last trading session.
The exchange symbol of ANIXA BIOSCIENCES INC is ANIX and it is listed on the Nasdaq exchange.
ANIX stock is listed on the Nasdaq exchange.
8 analysts have analysed ANIX and the average price target is 8.67 USD. This implies a price increase of 205.28% is expected in the next year compared to the current price of 2.84. Check the ANIXA BIOSCIENCES INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
ANIXA BIOSCIENCES INC (ANIX) has a market capitalization of 91.45M USD. This makes ANIX a Micro Cap stock.
ANIXA BIOSCIENCES INC (ANIX) currently has 5 employees.
ANIXA BIOSCIENCES INC (ANIX) has a support level at 2.83 and a resistance level at 3.02. Check the full technical report for a detailed analysis of ANIX support and resistance levels.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
ANIX does not pay a dividend.
ANIXA BIOSCIENCES INC (ANIX) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.39).
The outstanding short interest for ANIXA BIOSCIENCES INC (ANIX) is 1.35% of its float. Check the ownership tab for more information on the ANIX short interest.
ChartMill assigns a technical rating of 3 / 10 to ANIX. When comparing the yearly performance of all stocks, ANIX is a bad performer in the overall market: 73.66% of all stocks are doing better.
ChartMill assigns a fundamental rating of 3 / 10 to ANIX. ANIX has a great financial health rating, but its profitability evaluates not so good.
Over the last trailing twelve months ANIX reported a non-GAAP Earnings per Share(EPS) of -0.39. The EPS decreased by -21.88% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | N/A | ||
ROA | -58.14% | ||
ROE | -62.78% | ||
Debt/Equity | 0 |
ChartMill assigns a Buy % Consensus number of 83% to ANIX. The Buy consensus is the average rating of analysts ratings from 8 analysts.